Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Calgary
$27,000.00
Investigating T-cell factors associated with manufacturing failures of autologous chimeric antigen receptor T cells
FY 2025-26
Summary
Immunotherapy is a promising new avenue of cancer treatment that harnesses the power of the immune system to fight cancer. One type of immunotherapy, known as chimeric antigen receptor (CAR) T cell therapy, has shown success in the treatment of blood cancers. This therapy involves extracting and genetically modifying the patient’s own T cells (a type of white blood cell) to contain a CAR that targets the cancer cells. Producing CAR-T cell therapy involves a rigorous manufacturing process that has reported failure rates between 1-13%. This is a concern for both clinical trials and commercialized CAR-T cell products as it leads to treatment delay, wasted resources and increases the cost of this already expensive therapy. This project aims to identify factors that are associated with manufacturing failures. To do this, we will extensively characterize the pre-manufacture T cells from failed versus successful manufacturing runs from a Canadian-based academic CAR-T cell clinical trial known as CLIC-01 (NCT03765177). We hypothesize that there are likely intrinsic deficits such as exhaustion, premature cell aging, and a high specialization of the pre-manufacture T cells that promote manufacturing failure. To characterize the T cells, we will use experimental techniques that analyze the quality and function of the cells. This includes various methods to analyze the genetic material and an investigation into the metabolic activity of the T cells. Advancing our understanding of factors associated with manufacturing failures could lead to the ability to predict and mitigate this outcome, potentially prompting changes to the biomanufacturing process to increase manufacturing efficacy and timely treatment of patients.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
573138
Name
Robertson Haylee N
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating T-cell factors associated with manufacturing failures of autologous chimeric antigen receptor T cells
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
B Cell Malignancies; Cancer; Car-T Cells; Immunotherapy; Manufacturing Failures; T Cells
Abstract
Immunotherapy is a promising new avenue of cancer treatment that harnesses the power of the immune system to fight cancer. One type of immunotherapy, known as chimeric antigen receptor (CAR) T cell therapy, has shown success in the treatment of blood cancers. This therapy involves extracting and genetically modifying the patient’s own T cells (a type of white blood cell) to contain a CAR that targets the cancer cells. Producing CAR-T cell therapy involves a rigorous manufacturing process that has reported failure rates between 1-13%. This is a concern for both clinical trials and commercialized CAR-T cell products as it leads to treatment delay, wasted resources and increases the cost of this already expensive therapy. This project aims to identify factors that are associated with manufacturing failures. To do this, we will extensively characterize the pre-manufacture T cells from failed versus successful manufacturing runs from a Canadian-based academic CAR-T cell clinical trial known as CLIC-01 (NCT03765177). We hypothesize that there are likely intrinsic deficits such as exhaustion, premature cell aging, and a high specialization of the pre-manufacture T cells that promote manufacturing failure. To characterize the T cells, we will use experimental techniques that analyze the quality and function of the cells. This includes various methods to analyze the genetic material and an investigation into the metabolic activity of the T cells. Advancing our understanding of factors associated with manufacturing failures could lead to the ability to predict and mitigate this outcome, potentially prompting changes to the biomanufacturing process to increase manufacturing efficacy and timely treatment of patients.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Robertson, Haylee N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~